Guggenheim initiated coverage on Vigil Neuroscience with a new price target
$VIGL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $23.00